A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors
Jean‐Charles Soria(Inserm), Michael Millward(The University of Western Australia), T.R. Jeffry Evans(University of Glasgow), Charlotte Lemech(Unknown), Rastislav Bahleda(Institut Gustave Roussy), Leslie Swartz(Stellenbosch University), Ruth Plummer(National Health Service), Marie Ranson(University of Wollongong), Gérard Zalcman(Université Claude Bernard Lyon 1), Jolly Mazumdar(Howard Hughes Medical Institute), Sarah P. Blagden(Churchill Hospital), Noelia Nebot(Research Triangle Park Foundation), Sonya R Murray(Providence College), D. Gibson, Antoine Hollebecque(Institut Gustave Roussy), Jennifer Brown(Duke University), H.T. Arkenau(Sarah Cannon Research Institute), K R Auger(Providence College), Ronald A. Fleming(Research Triangle Park Foundation), Vijay Peddareddigari(GlaxoSmithKline (United States)), Emma Dean(AstraZeneca (United Kingdom)), R. Singh(Providence College), Hui Gan(Austin Hospital)
Cited by 145
Related Papers
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2015|1.3k